Endothelial effects of drugs designed to treat erectile dysfunction

Antonio Aversa, Massimiliano Caprio, Giuseppe M C Rosario, Giovanni Spera

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Erectile dysfunction (ED) and endothelial dysfunction are common in individuals with multiple cardiovascular risk factors (CRFs) and are longitudinal predictors of cardiovascular events. ED is associated with systemic endothelial cell activation/dysfunction independent from CRFs or from diffuse, unrecognized vascular damage. The pathogenesis of endothelial dysfunction and ED is intimately linked through decreased expression and activation of endothelial nitric oxide (NO) synthase and the subsequent physiologic actions of NO. Furthermore, reduced biologic activity of endothelium-derived NO links atherosclerosis to ED and underscores the role of altered endothelium in the pathogenesis of both conditions. Evidence-based data suggest that daily use of phosphodiesterase type-5, inhibitors (PDE5-i) improves endothelial and erectile functions and that this benefit is lost upon drug withdrawal. Daily PDE5-i may also improve lower tract urinary symptoms related to benign prostatic hyperplasia through a reduction of adrenergic overtone. The relevance for these drugs in the prevention of complications in internal medicine diseases, i.e. cardiovascular disease, clotting disorders and autoimmune disease is uncertain. Finally, endothelial dysfunction is present in testosterone deficiency syndromes and replacement therapy is able to revert ED and to improve endothelial function. Aim ofthe present review is to discuss the systemic effects ofdrugs designed to treat ED, such as testosterone and PDE5i, with regard to safety, unwanted effects and efficacy in improving endothelial function; finally, a goal-oriented approach to rehabilitation using daily vs. on-demand PDE5-i in difficult patients is discussed.

Original languageEnglish
Pages (from-to)3768-3778
Number of pages11
JournalCurrent Pharmaceutical Design
Volume14
Issue number35
DOIs
Publication statusPublished - 2008

Fingerprint

Erectile Dysfunction
Phosphodiesterase 5 Inhibitors
Pharmaceutical Preparations
Testosterone
Nitric Oxide
Lower Urinary Tract Symptoms
Nitric Oxide Synthase Type III
Prostatic Hyperplasia
Internal Medicine
Adrenergic Agents
Autoimmune Diseases
Endothelium
Blood Vessels
Atherosclerosis
Cardiovascular Diseases
Rehabilitation
Endothelial Cells
Safety

Keywords

  • Benign prostatic hyperplasia
  • Endothelial dysfunction
  • Internal medicine
  • LUTS
  • Nitric oxide
  • Phosphodiesterase type-5 inhibitors
  • Rehabilitation
  • Testosterone

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology

Cite this

Endothelial effects of drugs designed to treat erectile dysfunction. / Aversa, Antonio; Caprio, Massimiliano; Rosario, Giuseppe M C; Spera, Giovanni.

In: Current Pharmaceutical Design, Vol. 14, No. 35, 2008, p. 3768-3778.

Research output: Contribution to journalArticle

Aversa, Antonio ; Caprio, Massimiliano ; Rosario, Giuseppe M C ; Spera, Giovanni. / Endothelial effects of drugs designed to treat erectile dysfunction. In: Current Pharmaceutical Design. 2008 ; Vol. 14, No. 35. pp. 3768-3778.
@article{d8e7bed6c38a4ba3a28a7f57dc02055c,
title = "Endothelial effects of drugs designed to treat erectile dysfunction",
abstract = "Erectile dysfunction (ED) and endothelial dysfunction are common in individuals with multiple cardiovascular risk factors (CRFs) and are longitudinal predictors of cardiovascular events. ED is associated with systemic endothelial cell activation/dysfunction independent from CRFs or from diffuse, unrecognized vascular damage. The pathogenesis of endothelial dysfunction and ED is intimately linked through decreased expression and activation of endothelial nitric oxide (NO) synthase and the subsequent physiologic actions of NO. Furthermore, reduced biologic activity of endothelium-derived NO links atherosclerosis to ED and underscores the role of altered endothelium in the pathogenesis of both conditions. Evidence-based data suggest that daily use of phosphodiesterase type-5, inhibitors (PDE5-i) improves endothelial and erectile functions and that this benefit is lost upon drug withdrawal. Daily PDE5-i may also improve lower tract urinary symptoms related to benign prostatic hyperplasia through a reduction of adrenergic overtone. The relevance for these drugs in the prevention of complications in internal medicine diseases, i.e. cardiovascular disease, clotting disorders and autoimmune disease is uncertain. Finally, endothelial dysfunction is present in testosterone deficiency syndromes and replacement therapy is able to revert ED and to improve endothelial function. Aim ofthe present review is to discuss the systemic effects ofdrugs designed to treat ED, such as testosterone and PDE5i, with regard to safety, unwanted effects and efficacy in improving endothelial function; finally, a goal-oriented approach to rehabilitation using daily vs. on-demand PDE5-i in difficult patients is discussed.",
keywords = "Benign prostatic hyperplasia, Endothelial dysfunction, Internal medicine, LUTS, Nitric oxide, Phosphodiesterase type-5 inhibitors, Rehabilitation, Testosterone",
author = "Antonio Aversa and Massimiliano Caprio and Rosario, {Giuseppe M C} and Giovanni Spera",
year = "2008",
doi = "10.2174/138161208786898725",
language = "English",
volume = "14",
pages = "3768--3778",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "35",

}

TY - JOUR

T1 - Endothelial effects of drugs designed to treat erectile dysfunction

AU - Aversa, Antonio

AU - Caprio, Massimiliano

AU - Rosario, Giuseppe M C

AU - Spera, Giovanni

PY - 2008

Y1 - 2008

N2 - Erectile dysfunction (ED) and endothelial dysfunction are common in individuals with multiple cardiovascular risk factors (CRFs) and are longitudinal predictors of cardiovascular events. ED is associated with systemic endothelial cell activation/dysfunction independent from CRFs or from diffuse, unrecognized vascular damage. The pathogenesis of endothelial dysfunction and ED is intimately linked through decreased expression and activation of endothelial nitric oxide (NO) synthase and the subsequent physiologic actions of NO. Furthermore, reduced biologic activity of endothelium-derived NO links atherosclerosis to ED and underscores the role of altered endothelium in the pathogenesis of both conditions. Evidence-based data suggest that daily use of phosphodiesterase type-5, inhibitors (PDE5-i) improves endothelial and erectile functions and that this benefit is lost upon drug withdrawal. Daily PDE5-i may also improve lower tract urinary symptoms related to benign prostatic hyperplasia through a reduction of adrenergic overtone. The relevance for these drugs in the prevention of complications in internal medicine diseases, i.e. cardiovascular disease, clotting disorders and autoimmune disease is uncertain. Finally, endothelial dysfunction is present in testosterone deficiency syndromes and replacement therapy is able to revert ED and to improve endothelial function. Aim ofthe present review is to discuss the systemic effects ofdrugs designed to treat ED, such as testosterone and PDE5i, with regard to safety, unwanted effects and efficacy in improving endothelial function; finally, a goal-oriented approach to rehabilitation using daily vs. on-demand PDE5-i in difficult patients is discussed.

AB - Erectile dysfunction (ED) and endothelial dysfunction are common in individuals with multiple cardiovascular risk factors (CRFs) and are longitudinal predictors of cardiovascular events. ED is associated with systemic endothelial cell activation/dysfunction independent from CRFs or from diffuse, unrecognized vascular damage. The pathogenesis of endothelial dysfunction and ED is intimately linked through decreased expression and activation of endothelial nitric oxide (NO) synthase and the subsequent physiologic actions of NO. Furthermore, reduced biologic activity of endothelium-derived NO links atherosclerosis to ED and underscores the role of altered endothelium in the pathogenesis of both conditions. Evidence-based data suggest that daily use of phosphodiesterase type-5, inhibitors (PDE5-i) improves endothelial and erectile functions and that this benefit is lost upon drug withdrawal. Daily PDE5-i may also improve lower tract urinary symptoms related to benign prostatic hyperplasia through a reduction of adrenergic overtone. The relevance for these drugs in the prevention of complications in internal medicine diseases, i.e. cardiovascular disease, clotting disorders and autoimmune disease is uncertain. Finally, endothelial dysfunction is present in testosterone deficiency syndromes and replacement therapy is able to revert ED and to improve endothelial function. Aim ofthe present review is to discuss the systemic effects ofdrugs designed to treat ED, such as testosterone and PDE5i, with regard to safety, unwanted effects and efficacy in improving endothelial function; finally, a goal-oriented approach to rehabilitation using daily vs. on-demand PDE5-i in difficult patients is discussed.

KW - Benign prostatic hyperplasia

KW - Endothelial dysfunction

KW - Internal medicine

KW - LUTS

KW - Nitric oxide

KW - Phosphodiesterase type-5 inhibitors

KW - Rehabilitation

KW - Testosterone

UR - http://www.scopus.com/inward/record.url?scp=61449225888&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=61449225888&partnerID=8YFLogxK

U2 - 10.2174/138161208786898725

DO - 10.2174/138161208786898725

M3 - Article

C2 - 19128229

AN - SCOPUS:61449225888

VL - 14

SP - 3768

EP - 3778

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 35

ER -